Rubella vaccines: past, present and future

J. M. BEST

Department of Virology, United Medical and Dental Schools and Guy's and St Thomas's Hospitals, St Thomas' Campus, Lambeth Palace Rd, London SE1 7EH

THE PAST

The association between rubella in pregnancy and congenital anomalies was first reported 50 years ago, by N. McAlister Gregg, an Australian ophthalmologist [1]. During the next 20 years his findings were confirmed by others (reviewed in [2]). However, the first reports of the isolation of rubella virus in cell cultures and development of tests for neutralizing antibodies were not published until 1962 [3, 4]. Subsequent studies conducted in the UK and North America during a pandemic of rubella in 1963–4, were therefore able to make a more accurate estimate of the risks of maternal rubella at different stages of pregnancy. It was estimated that about 30000 rubella-damaged babies were born in the USA alone in 1963–4 [5]. This emphasized the importance of developing a vaccine to prevent infection in pregnancy and thereby, the birth of babies with rubella-induced congenital defects.

The main historical events associated with rubella and the development and use of rubella vaccines are listed in Table 1.

Development of rubella vaccines

Early attempts to produce an inactivated rubella vaccine were unsuccessful, as it was impossible to produce sufficient quantities of high titre virus in the cells of choice. Multiple inoculations of $10^4$–$10^5$ TCID50 of virus, inactivated with β-propiolactone, ultraviolet light or irradiation were required to elicit an antibody response in monkeys [6]. Studies on inactivated vaccines were discontinued when it was reported that rubella virus could be attenuated by multiple passage in cell cultures.

The first attenuated strain of rubella virus was produced by passaging rubella virus, isolated in 1961 from a US military recruit (M33), 77 times in vervet monkey kidney cell cultures to give the prototype vaccine HPV77 (high-passage virus-77) [7]. This attenuated strain was given a further five passages in duck embryo fibroblasts, since avian cells are less likely to carry extraneous agents than monkey kidney cells [8, 9]. This strain, HPV77. DE5, was licensed for use in the USA and many countries in Europe in 1969–70. The HPV77. DK12 vaccine strain was produced by passing HPV77 12 times in dog kidney cell cultures [10]. Although it was licensed in 1969, its use was discontinued, as the incidence of adverse reactions was unacceptably high [11, 12].

A number of other attenuated strains have been developed (Table 2). The Cendehill strain was licensed for use in the USA in 1969 and in the UK and other
Table 1. Main historical events

<table>
<thead>
<tr>
<th>Event</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>First report of congenital rubella [1]</td>
<td>1941</td>
</tr>
<tr>
<td>Rubella virus isolated in cell cultures;</td>
<td>1962</td>
</tr>
<tr>
<td>specific antibodies measured by neutralization test</td>
<td></td>
</tr>
<tr>
<td>Pandemic of rubella; 30,000 cases of congenital rubella reported in the USA</td>
<td>1963/4</td>
</tr>
<tr>
<td>Attenuated strains of rubella developed and first vaccine trials</td>
<td></td>
</tr>
<tr>
<td>HPV77.DE5 and Cendehill vaccine strains licensed in the USA</td>
<td>1969</td>
</tr>
<tr>
<td>Cendehill vaccine strain licensed in the UK</td>
<td>1970</td>
</tr>
<tr>
<td>MMR1* licensed in the USA</td>
<td>1971</td>
</tr>
<tr>
<td>RA27/3 vaccine strain licensed in the UK</td>
<td>1972</td>
</tr>
<tr>
<td>RA27/3 replaced HPV77.DE5 vaccine strain in the USA</td>
<td>1979</td>
</tr>
<tr>
<td>MMR† licensed in the UK</td>
<td>1988</td>
</tr>
</tbody>
</table>

*MMR1 contained measles virus (Moraten strain), mumps virus (Jeryl Lynn strain) and rubella virus (HPV77.DE5 strain).
†MMR vaccines licensed in the UK contain measles virus (Schwartz strain), mumps virus (Urabe AM/9 or Jeryl Lynn strains) and rubella virus (RA27/3 strain).

European countries in 1970. This virus was isolated from a case of postnatally acquired rubella in 1963 at the University of Louvain, Belgium. It was attenuated by 51 passages in primary rabbit kidney cell cultures, derived from a select colony of rabbits bred and reared under pathogen-free conditions, which were shown to be free of adventitious agents [13, 14]. A reliable index of attenuation was the inability of the attenuated strain to induce an antibody response in rabbits [15].

The Cendehill strain has been widely used in the USA and Europe, especially for adult women, as it is less reactogenic than the HPV77.DE5 and RA27/3 vaccine strains [16, 17].

The RA27/3 vaccine strain was isolated directly in human diploid fibroblasts (WI-38) from explant cultures established from a kidney of a rubella-infected fetus and attenuated by 27–30 passages in WI-38 fibroblasts at temperatures between 30 and 35 °C. The name RA27/3 is derived from ‘rubella abortus, 27th specimen, third explant’ [18].

Four other attenuated strains of rubella virus have been developed and are used in Japan (Table 2) [19, 20]. The BRD-2 vaccine strain has been developed at the National Vaccine and Serum Institute in Beijing, China [21].

Early vaccine trials

The aim of the first vaccine trials was to assess reactogenicity and immunogenicity and also to determine whether virus was transmitted to susceptible contacts. This was of considerable importance, as transmission to susceptible pregnant contacts had to be avoided, since it was not known whether the attenuated strains would cause congenital defects if acquired in early pregnancy. Rhesus monkeys were used for the first experimental trials of rubella vaccine strains, because the pattern of virus excretion and antibody responses were similar to those observed in humans [22]. Following parenteral administration, the HPV77 strain was shown to induce neutralizing antibody responses which were comparable to those observed following administration of a low
Rubella vaccines: past, present and future

Table 2. Attenuated rubella virus vaccine strains

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Strain derivation</th>
<th>Attenuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV77</td>
<td>Army recruit with rubella (1961)</td>
<td>VMK (77)*</td>
</tr>
<tr>
<td>HPV77. DE5</td>
<td>As above</td>
<td>VMK (77); duck embryo (5)</td>
</tr>
<tr>
<td>Cendehill</td>
<td>Urine from a case of postnatally acquired rubella (1963)</td>
<td>VMK (3); primary rabbit kidney (51)</td>
</tr>
<tr>
<td>RA27/3</td>
<td>Kidney of rubella-infected fetus (1964)</td>
<td>Human embryonic kidney (4); WI-38 fibroblasts (17-25)</td>
</tr>
<tr>
<td>DCRB 19</td>
<td>Throat swab from patient in Tokyo (1967)</td>
<td>VMK (1); bovine kidney (53); rabbit kidney (3)</td>
</tr>
<tr>
<td>KRT</td>
<td>Throat swab from patient in Matsue city (1968) – Takahashi (MAT) strain</td>
<td>testicle (36); primary rabbit kidney (1)</td>
</tr>
<tr>
<td>MEQ12</td>
<td>Throat washing from patient in Osaka (1966) – Matsuura strain</td>
<td>VMK (14); Chick amnion (65); quail embryo fibroblast cells (11)</td>
</tr>
<tr>
<td>TO-336</td>
<td>Pharyngeal secretion from child with postnatally acquired rubella, Toyama, Japan (1967)</td>
<td>VMK (7); primary guinea-pig kidney (20); primary rabbit kidney (3)</td>
</tr>
<tr>
<td>SK</td>
<td>Throat washing from patient in Kumamoto (1969) – Matsuba strain</td>
<td>VMK (1); swine kidney (60); rabbit kidney (6)</td>
</tr>
<tr>
<td>BRD-2</td>
<td>Child with postnatally acquired rubella in China (1980)</td>
<td>Human diploid cells (30)</td>
</tr>
<tr>
<td></td>
<td>2BS strain</td>
<td>VMK, vervet monkey kidney.</td>
</tr>
</tbody>
</table>

* Number of passages in parentheses.

passage strain of virus. Monkeys given the attenuated strain did not transmit infection to susceptible cage contacts and when challenged by the intramuscular or intravenous route with a non-attenuated virus, they were protected from reinfection. The attenuated Cendehill strain was less immunogenic than the virulent virus when inoculated subcutaneously (SC) into monkeys and not infectious when inoculated intranasally (IN) [15]. Attenuation of RA27/3 was tested by inoculating human volunteers with different passage levels of the virus [23].

Trials were then carried out in institutional communities, in order to confirm immunogenicity and lack of significant reactogenicity and transmissibility following subcutaneous administration of vaccine. Trials were carried out in adults living in religious communities, prisoners, children living in institutions and boarding schools, mother and baby pairs, husband and wife, and children in families living in isolated conditions [16, 17, 24]. The lack of transmission to susceptible contacts may be due to a reduction in virus replication or to low infectivity, as virus is shed in the nasopharynx from approximately day 7 to day 25 after immunization [25, 26].

Once it had been established that transmission to susceptible contacts did not occur, more extensive trials were conducted in ‘open’ communities, which confirmed that the attenuated virus strains were safe and effective and that seroconversion occurred in > 95% of susceptible vaccinees [16, 17]. It was also
shown that rubella could be successfully combined with measles and mumps to give a triple vaccine, which induced antibodies to all three viruses [27, 28].

**THE PRESENT**

**Vaccines available**

The RA27/3 strain is now the most widely used rubella vaccine strain [20]. It replaced the HPV77.DE5 strain in the USA in 1979, since it was considered that the antibody response and protection afforded by this strain more closely resembled that induced by naturally-acquired infection than that induced by the other attenuated strains. The RA27/3 strain is included in MMR (measles, mumps and rubella) vaccines produced in the USA and western Europe. Other vaccine strains are used in Japan and China (Table 2).

**Administration of rubella vaccines**

Rubella vaccines are usually administered subcutaneously in a 0.5 ml volume containing no less than 1000 TCID50 rubella virus. Before reconstitution, rubella (and MMR) vaccines must be stored at temperatures of 2-8 °C or lower and must be protected from light, which may inactivate the virus. They must be transported at 10 °C or below or on dry ice. Reconstituted vaccine should be discarded if not used within 1 h.

The RA27/3 strain, unlike Cendehill and HPV77.DE5, will induce an immune response when at least 1000 TCID50 is administered IN; it is not transmitted to susceptible contacts [23, 29]. The IN route is not considered suitable for routine use, however, as the vaccinator must be experienced and the recipient must be cooperative and free from respiratory infection and obstruction [30].

**Contraindications**

It is recommended that rubella vaccine should not be given to patients whose immunological response is impaired, as a result of disease or treatment with immunosuppressive drugs. However, there are no reports of adverse events in such persons. Rubella vaccine should not be given within 3 weeks of another live vaccine or BCG. Passively acquired antibodies may interfere with the immune response and immunization should therefore be delayed for about 3 months after a blood transfusion or a dose of human immunoglobulin. Although recent administration of anti-D immune globulin is not a contraindication to post-partum immunization, it is advisable to confirm seroconversion 8–12 weeks later. Pregnancy is an absolute contraindication to immunization, since the vaccine strains may be transmitted transplacentally (see below). In the UK it is recommended that pregnancy should be avoided for 1 month after rubella or MMR immunization [31], while in the USA an interval of 3 months is recommended [32]. Thus, the vaccinator should ensure that effective contraceptive precautions are being taken before immunizing susceptible women of child-bearing age.

Contraindications to rubella immunization have been discussed in more detail elsewhere [31–33].
Adverse reactions

Rubella vaccines are generally very well tolerated. Adverse reactions may occur but are less severe than those experienced following naturally-acquired infection and are more likely to occur in adults than in children. Lymphadenopathy, fever, rash, arthralgia (painful joints) or arthritis (joint swelling or limitation of movement) may occur between 10 days and 4 weeks after immunization of susceptibles. The onset of joint symptoms is usually between 13 and 21 days after immunization, a few days after the appearance of lymphadenopathy or rash; they persist for between 1 day and 3 weeks. Lymphadenopathy may not be noticed, but occasional vaccinees complain of enlarged and tender lymph nodes. Rash may occur in up to 25% RA27/3 vaccinees (Table 3), but is usually faint, macular and fleeting. There have been very occasional reports of transient peripheral neuritic complaints, such as paresthesias and pain in the arms and legs [34]. Petechial or purpuric rashes are not seen after rubella immunization, but mild thrombocytopenia has been recorded following immunization with RA27/3 and Cendehill [35, 36].

Joint symptoms, which may occur in up to 52% adult women with naturally-acquired rubella [37], are less frequent and less severe following immunization. The peripheral joints, i.e. knees, finger joints, wrists and ankles, are most frequently affected, but symptoms are generally mild and seldom result in time lost from work [25, 37]. The incidence of joint symptoms following both natural infection and immunization of susceptibles increases with age [25, 38]. Weibel and colleagues [38] observed that joint symptoms occurred in 7.5% persons aged 12-25 and in 58.3% of those aged 26-41 following immunization with HPV77. DE5. Best and her colleagues [25] reported that joint symptoms occurred more frequently in HPV77. DE5 vaccinees (38.7%) and RA27/3 vaccinees (41.7%) than in Cendehill (22.9%) and TO-336 (17.6%) vaccinees. Overall, joint symptoms lasting 7 days or more were seen in 5 of 136 (3.7%) vaccinees. Tingle and his colleagues [37] reported recurrent arthropathy for longer than 18 months in 2 of 44 adult females given RA27/3. Joint reactions with HPV77-derived vaccines tend to be more severe. The HPV77. DK12 vaccine, although licensed in the USA in 1969, was soon withdrawn, as it induced particularly severe joint reactions, even in children, some of whom experienced an intermittent arthritis for up to 3 years [11, 12].

It has been suggested that joint symptoms may result from infection of synovial cells, from the formation of immune complexes or to an autoimmune reaction. Rubella virus has been isolated from joint aspirates from vaccinees with vaccine-induced arthritis [39, 40] and both wild and attenuated strains of rubella will replicate in human synovial cell cultures [41, 42]. Studies of immune complexes in the serum of vaccinees with joint symptoms have yielded conflicting results [43-45]. However, if virus persists in synovial cells [40] and rubella-specific antibodies are produced in joints [46], it is possible that immune complexes could be produced locally in the joints.

Hormonal factors may also play a role in the development of joint symptoms. Joint symptoms do not usually occur in pre-pubertal girls [17] and occur less frequently in men [37] and in women vaccinated in the immediate post-partum...
Table 3. Vaccine-associated reactions following vaccination with the RA27/3 vaccine strain [25]

<table>
<thead>
<tr>
<th></th>
<th>RA27/3</th>
<th>Controls*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>36</td>
<td>39</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>16 (44%)</td>
<td>14 (35%)</td>
</tr>
<tr>
<td>Rubelliform rash</td>
<td>9 (25%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Joint symptoms</td>
<td>15 (42%)</td>
<td>0</td>
</tr>
</tbody>
</table>

*Unvaccinated persons of the same age range followed up over a 30-day period.

It has been suggested that rubella virus is a possible cause of chronic inflammatory joint disease. The virus has been isolated from the peripheral blood lymphocytes (PBLs) from a small number of adult women with joint symptoms persisting for a few years after rubella immunization or natural infection by a group working in British Columbia [49, 50]. They also isolated rubella virus from PBLs and synovial fluid mononuclear cells from 7 of 19 (35%) children with chronic inflammatory joint disease [51]. These results have not been confirmed by others, but it is possible that they may be explained by the persistence of rubella virus in circulating lymphocytes or in the joints. Further evidence for the possible persistence of rubella virus comes from the detection of rubella-specific IgM responses for up to 4 years after immunization ([52], S. O'Shea, J. M. Best and J. E. Banatvala, unpublished results).

Risks of vaccination in pregnancy

Rubella vaccination is contraindicated during pregnancy because it has been shown that the virus will cross the placenta following vaccination (reviewed in [53]). However, when 514 susceptible women inadvertently immunized within 3 months of conception or during pregnancy, who elected to go to term, were followed up, there was no evidence of congenital abnormalities compatible with congenital rubella among their infants, although 9 of 400 babies tested had evidence of congenital infection (Table 4) [32, 53]. G. Enders, personal communication; P. Tookey, personal communication; M. L. Lindegren, personal communication). However, 94 of the 324 women in the US study had received the HPV77, DE5 or Cendehill vaccine strains, which are no longer in use (see Vaccines available, p. 22). The Rubella Vaccination in Pregnancy Study is continuing to collect data in the UK on the risks of vaccination in pregnancy, although the study in the USA has been discontinued. Although pregnancy is a contraindication for vaccination, vaccination is not normally a reason for termination of pregnancy, although the decision should be left to the patient and her obstetrician. However, it should be noted that in the US studies, only about a third of the women followed
Rubella vaccines: past, present and future

Table 4. Combined data for risk of CRS in infants born to susceptible women whose pregnancies were complicated by rubella immunization

<table>
<thead>
<tr>
<th>Country</th>
<th>Within 3 months of conception or during pregnancy</th>
<th>Between 1 week before and 4 weeks after conception</th>
<th>Evidence of infection</th>
<th>Abnormalities compatible with CRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>321</td>
<td>113/312 (36%)</td>
<td>6/222 (2.7%)</td>
<td>0/324</td>
</tr>
<tr>
<td>Federal Republic of Germany</td>
<td>144</td>
<td>NK</td>
<td>3/144 (2.1%)</td>
<td>0/144</td>
</tr>
<tr>
<td>Sweden</td>
<td>5</td>
<td>NK</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>UK</td>
<td>45</td>
<td>9/45 (20%)</td>
<td>1/30 (3.3%)</td>
<td>0/42</td>
</tr>
<tr>
<td>Totals</td>
<td>515</td>
<td>122/357 (34%)</td>
<td>10/401 (2.5%)</td>
<td>0/515</td>
</tr>
</tbody>
</table>

NK, not known.

up were vaccinated in the high risk period between 1 week before to 4 weeks after conception (Table 4) [32, 54]. The estimated risk of major malformations attributable to RA27/3 vaccine is between 0 and 1.6%, based on the binomial distribution with 95% confidence limits [32, 54], which is less than the risk of major malformation in unselected pregnancies (2–3%). The observed risk with all vaccine strains to date is zero.

Most adult women who are vaccinated have been screened and shown to be susceptible to rubella. However, in cases where the woman has not been tested, it is often possible to determine her immune status retrospectively, by testing a serum sample taken within 8 weeks of immunization for rubella-specific IgM, which can usually be detected if there was no prior immunity [55, 56].

Immune responses

In seronegative vaccinees. Vaccine trials have shown that all licensed rubella vaccines induce an antibody response [16, 17]. Haemagglutination inhibition (HAI) antibodies usually develop between 10 and 28 days after vaccination [57–59], although a response may occasionally be delayed. HAI antibodies are usually 4–8-fold lower in vaccinees than following natural infection. The RA27/3 strain induces antibodies which most closely resemble those resulting from natural infection [59, 60]. Cusi and colleagues [61, 62] found that antibodies specific for all three structural proteins, E1, E2 and C, could be detected in sera taken 1 month after immunization with RA27/3, but only antibodies to E1 of wild-type virus were found to persist for 3 years or more in all eight vaccinees tested.

About 5% of vaccinees fail to seroconvert [16, 17]. Failure to seroconvert may be due to a concurrent infection and such persons will respond when revaccinated. Some women who apparently fail to seroconvert may have a low level of pre-existing antibody, which was not detected by the screening test used. Such women should be retested by more sensitive assays, such as enzyme immunoassay (EIA) or latex agglutination (LA) (see below).

Studies on the long-term persistence of vaccine-induced antibodies have shown that immunity is probably lifelong in most vaccinees; antibodies have been
detected in 2066 of 2154 (95.9%) vaccinees who were tested between 9 and 21 years after immunization (Table 5). These results, however, are influenced by the sensitivity of the techniques used to measure rubella antibodies. Horstmann and her colleagues [64] reported 16% of HPV77.DE5 vaccinees were seronegative by HAI 11–12 years after immunization. However, HAI is a relatively insensitive technique and studies which have used several different techniques, including EIA and LA, have found that a smaller percentage of vaccinees were seronegative [66, 68, 70]. Although O'Shea and colleagues [66], working in the UK, showed that 96% of 117 vaccinees had antibodies > 15 i.u./ml when tested 10–21 years after immunization by single radial haemolysis (SRH), EIA and LA, 10% of their vaccinees had antibody concentrations < 15 i.u./ml when tested 5–8 years after immunization [71]. The increase in seropositivity seen suggests that reinfection had boosted antibody concentrations, as rubella virus continued to circulate in the UK at that time. A study conducted in schoolchildren in Massachusetts, where rubella had been virtually eliminated, revealed that 87% of children given HPV77.DE5 10–14 years earlier had antibody concentrations below 7 i.u./ml [70]. In general, Cendehill and HPV77.DE5 vaccinees are more likely to have low antibody concentrations, become seronegative and exhibit booster antibody responses than RA27/3 vaccinees [65, 66], which is why the RA27/3 vaccine strain is now the most widely used.

Rubella-specific IgM can be detected in serum of most vaccinees between 3 and 8 weeks after immunization if sensitive techniques are employed [56, 57, 59]. Using an M-antibody capture radioimmunoassay (MACRIA), low levels of IgM antibodies have been detected in 18 of 53 (33.9%) vaccinees 1 year after immunization [52] and in 7 of the 18, 3 years after immunization (S. O'Shea, J. M. Best and J. E. Banatvala, unpublished results).

Rubella-specific IgA can be detected in both the serum and nasopharyngeal secretions following administration of all vaccine strains, as well as after naturally acquired infection [59, 72, 73] and may persist in the serum for 10–12 years after immunization [59]. In the serum there is apparently a transient oligomeric (10S) IgA response [74] and a persistent 7S IgA response [59]. Nasopharyngeal IgA antibodies have been detected in 80% of vaccinees 6 weeks after immunization [59]. The highest concentrations were seen in vaccinees given RA27/3, SC or IN. Nasopharyngeal IgA antibodies persisted in RA27/3 vaccinees for up to 5 years, but for only 2–3 years after immunization with the Cendehill, HPV77.DE5 and TO-336 strains [59].

There have been few studies on cell mediated immune responses to rubella virus. Lymphocyte transformation responses are lower after immunization than after naturally-acquired infection and may be difficult to detect [75–77].

In seropositive vaccinees. Not all those with low levels of antibody will develop booster responses after immunization with RA27/3 [52, 78, 79]. Väänänen and his colleagues [80] reported only a small increase in antibody titre in persons with low levels of antibody, while 28% had no increase in titre as measured by SRH. Some subjects exhibit only a transient rise in antibody concentration [81, 82]. In the UK it is current practice to vaccinate women with rubella antibodies < 15 i.u./ml. The PHLS Working Party on the Laboratory Diagnosis of Rubella [83] recommended that revaccination of women with a documented history of two or
Rubella vaccines: past, present and future

Table 5. Persistence of antibodies 9–21 years after immunization of seronegative persons—comparison of four vaccines

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>No. seronegative/no. tested (% seronegative)</th>
<th>Years after vaccination</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA27/3</td>
<td>1/94 (1%)</td>
<td>12</td>
<td>H. Zealley and E. Edmund*</td>
</tr>
<tr>
<td></td>
<td>1/21 (4.7%)</td>
<td>15</td>
<td>Hillary and Griffith [63]</td>
</tr>
<tr>
<td></td>
<td>0/35</td>
<td>14</td>
<td>Horstmann et al. [64]</td>
</tr>
<tr>
<td></td>
<td>0/115</td>
<td>10–21</td>
<td>Enders and Nickerl [65]</td>
</tr>
<tr>
<td></td>
<td>1/48 (2.1%)</td>
<td></td>
<td>O’Shea et al. [66]</td>
</tr>
<tr>
<td>Total</td>
<td>3/313 (1%)</td>
<td>10–21</td>
<td></td>
</tr>
<tr>
<td>Cendehill</td>
<td>3/145 (2%)</td>
<td>12</td>
<td>H. Zealley and E. Edmund*</td>
</tr>
<tr>
<td></td>
<td>3/319 (1%)</td>
<td>15</td>
<td>Just et al. [67]</td>
</tr>
<tr>
<td></td>
<td>18+/400 (4.5%)</td>
<td>16</td>
<td>Chu et al. [68]</td>
</tr>
<tr>
<td></td>
<td>2/102 (2%)</td>
<td>14–17</td>
<td>Enders and Nickerl [65]</td>
</tr>
<tr>
<td></td>
<td>1+40 (2.5%)</td>
<td>10–21</td>
<td>O’Shea et al. [66]</td>
</tr>
<tr>
<td>Total</td>
<td>27/1006 (2.7%)</td>
<td>10–21</td>
<td></td>
</tr>
<tr>
<td>TO-336</td>
<td>0/25</td>
<td>9</td>
<td>Hoshino et al. [69]</td>
</tr>
<tr>
<td></td>
<td>0/11</td>
<td>12–13</td>
<td>O’Shea et al. [66]</td>
</tr>
<tr>
<td>Total</td>
<td>0/36</td>
<td>9–13</td>
<td></td>
</tr>
<tr>
<td>HPV77.DE5</td>
<td>13/79 (16%)</td>
<td>11–12</td>
<td>Horstmann et al. [64]</td>
</tr>
<tr>
<td></td>
<td>26+/302 (8.7%)</td>
<td>10–14</td>
<td>Orenstein et al. [70]</td>
</tr>
<tr>
<td></td>
<td>18/385 (4.7%)</td>
<td>16</td>
<td>Chu et al. [68]</td>
</tr>
<tr>
<td></td>
<td>0/15</td>
<td>14</td>
<td>Enders and Nickerl [65]</td>
</tr>
<tr>
<td></td>
<td>1/18 (5.5%)</td>
<td>10–21</td>
<td>O’Shea et al. [66]</td>
</tr>
<tr>
<td>Total</td>
<td>58/799 (7.3%)</td>
<td>10–21</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>88/2154 (4.1%)</td>
<td>9–21</td>
<td></td>
</tr>
</tbody>
</table>

* Personal communication, 1983.
† < 7 i.u./ml.
‡ This vaccinee was seronegative by SRH and HAI, but had antibodies detectable by EIA and LA.

more rubella vaccinations was not necessary if rubella antibodies were detected by two different assays, even if antibody concentrations were < 15 i.u./ml.

Vaccine efficacy and reinfection

Both natural infection and immunization provide protection from symptomatic reinfection, except in rare cases. However, asymptomatic reinfection, as demonstrated by a significant rise in antibody titre, may occur after prolonged exposure to a case of rubella or following experimental challenge. Specific IgM responses may also be detected if sensitive assays are used, but are generally lower and more transient than IgM responses seen in primary infection [84, 85]. Experimental challenge studies have demonstrated that reinfection is more likely to occur in those with vaccine-induced immunity than in those whose immunity is naturally acquired, and less likely to occur in RA27/3 vaccinees than in those vaccinated with HPV77.DE5 and Cendehill [26, 84].

Reinfection in the first trimester of pregnancy will not present a hazard to the developing fetus, unless it is accompanied by a viraemia. There is evidence from experimental studies that viraemia may occasionally occur following challenge.
O’Shea and her colleagues [84] detected a viraemia in 1 of 19 vaccinees with a low level of pre-existing antibodies (< 15 i.u./ml) following IN challenge with high titre RA27/3. Schiff and his colleagues [86] detected viraemia in 3 of 6 vaccinees with low or undetectable antibodies following IN challenge with a large dose (approximately 1000 TCID50) of an unattenuated strain of rubella virus. Although the majority of women who have experienced reinfection in pregnancy have delivered infants without evidence of congenital infection, there are a small number of well documented cases, where an infant with congenital rubella syndrome has been born to a woman who had rubella antibodies prior to the affected pregnancy [87–89]; some of these women had a history of vaccination. Studies are in progress to determine whether these women have a defect in their immune responses to rubella, such as a failure to mount a cell mediated immune response or lack of antibodies to the ‘protective’ epitope of the virus.

THE FUTURE

Although the attenuated rubella vaccines in use are efficacious and do not usually induce adverse reactions in children, the RA27/3 strain may induce joint symptoms in up to 42% of susceptible adult women following vaccination and a small proportion may have persistent or recurrent symptoms. In addition, the vaccine should not be given to pregnant women or to immunocompromised persons, as discussed above. It is probable that in the future it will be considered desirable to produce subunit vaccines, containing only the ‘protective’ epitopes of the virus, by recombinant techniques or as peptides [90]. Such techniques are already used to produce hepatitis B vaccine and several other viral vaccines, which are currently being evaluated [91]. The ‘protective’ epitopes of rubella virus have not yet been identified, although three epitopes which react with HA1 and neutralizing antibodies have been described on E1 [92, 93]. No significant antigenic variation in the E1 glycoprotein was detected when nine strains of rubella were compared using a panel of 31 monoclonal antibodies [J. M. Best and colleagues, unpublished results]. However, experiments which compared the reactivity of sera from vaccinees with antigens prepared from wild-type and attenuated strains have suggested that antigenic differences may occur in E2 or C [62, 94, 95]. The rubella virus genome has been cloned and sequenced [96] and the viral structural proteins (E1 and E2) have been expressed in Escherichia coli, COS cells and baculovirus [97–101, P. G. Sanders and J. M. Best, unpublished results]. It remains to be determined which expression system will be found to be most suitable for production of the viral polypeptides required to induce ‘protective’ antibodies. This will depend on the post transcriptional modification of the proteins required for immunogenicity in man and the ability to purify the proteins produced [90].

REFERENCES

Rubella vaccines: past, present and future

26 Harcourt GC, Best JM, Banatvala JE. HLA antigens and responses to rubella vaccination. J Hyg 1975; 83: 405–12.
Rubella vaccines: past, present and future